Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease

Código QR

Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease

Background: Patients undergoing complex percutaneous coronary intervention (PCI) have an increased risk of cardiovascular events. Whether potent antiplatelet therapy after complex PCI improves outcomes in patients with stable coronary artery disease (SCAD) remains unclear.Objectives: To assess the e...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ziwei Xi, Jianan Li, Hong Qiu, Tingting Guo, Yong Wang, Yang Li, Jianfeng Zheng, Kefei Dou, Bo Xu, Yongjian Wu, Shubin Qiao, Weixian Yang, Yuejin Yang, Runlin Gao
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	ticagrelor clopidogrel antiplatelet therapy complex PCI stable coronary artery disease Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/23912a509bd14d68ab05f3d2dafa8513
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Impact of Routine Platelet Reactivity Testing with VerifyNow Assay on Antiplatelet Choice After Percutaneous Coronary Intervention
por: Mshelbwala FS, et al.
Publicado: (2020)

Response to antiplatelet therapy in patients undergoing invasive treatment due to acute coronary syndrome complicated by cardiogenic shock
por: Wiktor Kuliczkowski, et al.
Publicado: (2020)

Strategic approach to developing a self-microemulsifying drug delivery system to enhance antiplatelet activity and bioavailability of ticagrelor
por: Na YG, et al.
Publicado: (2019)

Ticagrelor – toward more efficient platelet inhibition and beyond
por: Kubisa MJ, et al.
Publicado: (2018)

Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention
por: Kreutz RP, et al.
Publicado: (2016)

Infections Deaths in the PLATO Trial
por: Victor Serebruany, et al.
Publicado: (2021)

Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes
por: Gjin Ndrepepa, et al.
Publicado: (2021)

Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre‐Specified Analysis of the GLOBAL LEADERS Trial
por: Pascal Vranckx, et al.
Publicado: (2021)

Influence of sex on outcomes after percutaneous coronary intervention in patients over 75 years of age with coronary heart disease
por: Liu Y, et al.
Publicado: (2014)

Promoting vascular healing using nanofibrous ticagrelor-eluting stents
por: Lee CH, et al.
Publicado: (2018)

The influence of acute coronary syndrome on the levels of clopidogrel active metabolite and platelet inhibition in patients with and without CYP2C19 and ABCB1 gene polymorphisms
por: Tomasz Wójcik, et al.
Publicado: (2021)

Prolonged ventricular pause associated with ticagrelor use: A case report
por: Alaa Rahhal, et al.
Publicado: (2021)

COMPARISON OF INTRACORONARY VERAPAMIL VS ADENOSINE FOR RESTORATION OF CORONARY BLOOD FLOW POST PERCUTANEOUS CORONARY INTERVENTION (PCI) IN PATIENTS WITH NO-REFLOW
por: Mohsin Saif, et al.
Publicado: (2020)

ZERO-CROSSING DERIVATIVE SPECTROPHOTOMETRY AND LIQUID CHROMATOGRAPHIC METHOD FOR THE QUANTITATIVE DETERMINATION OF CLOPIDOGREL IN PRESENCE OF HMG CO-A REDUCTASE INHIBITORS
por: SULTANA,NAJMA, et al.
Publicado: (2013)

Prognostic significance of Troponin I in patients undergoing primary percutaneous coronary intervention
por: Pratik Sudhir Sane, DNB, et al.
Publicado: (2021)

ABCB1 polymorphism in clopidogrel-treated Montenegrin patients
por: Mugosa Snezana, et al.
Publicado: (2021)

Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction with ST Segment-Elevation: Effect on the Severity of Ischemic Mitral Regurgitation
por: Mohammad Aly Hammad, et al.
Publicado: (2021)

Clinical Impact of Single and Dual Antiplatelet Therapy Beyond 12 Months on Ischemic Risk in Patients With Acute Myocardial Infarction
por: Ji Woong Roh, et al.
Publicado: (2021)

Clopidogrel-Induced Interstitial Lung Disease: A Case Report
por: An J, et al.
Publicado: (2021)

Efficiency of invasive revascularization for acute coronary syndrome with ST elevation: first results of Regional Vascular Center of the Buryat Republic
por: L. B. Sodnomova, et al.
Publicado: (2017)

Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
por: Abdelmoniem Moustafa, et al.
Publicado: (2019)

Mechanical circulatory support during high-risk percutaneous coronary intervention in a young male patient
por: Artur Pawlik, et al.
Publicado: (2020)

Impact of Pre-Revascularization and Post-Revascularization Cardiac Arrest on Survival Prognosis in Patients With Acute Myocardial Infarction and Following Emergency Percutaneous Coronary Intervention
por: Changzuan Zhou, et al.
Publicado: (2021)

Antiplatelets in acute coronary syndrome in Poland – from guidelines to clinical practice
por: Stanisław Tubek, et al.
Publicado: (2021)

Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor
por: Nikita Lomakin, et al.
Publicado: (2019)

ANTIPLATELET AGENTS IN THE TREATMENT AND SECONDARY PREVENTION OF ISCHEMIC STROKE (REVIEW OF LITERATURE)
por: E. Y. Kitaeva, et al.
Publicado: (2017)

TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention
por: Johny Nicolas, et al.
Publicado: (2020)

Manejo perioperatorio de pacientes usuarios de antiagregantes plaquetarios
por: Nazar J.,Claudio, et al.
Publicado: (2018)

Association between Paraoxonase-1 p.Q192R Polymorphism and Coronary Artery Disease susceptibility in the Colombian Population
por: Corredor-Orlandelli D, et al.
Publicado: (2021)

Intravascular Ultrasound Guidance Improves the Long-term Prognosis in Patients with Unprotected Left Main Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
por: Jian Tian, et al.
Publicado: (2017)

Effect of prasugrel versus ticagrelor on coronary microperfusion in ST elevation myocardial infarction patients undergoing percutaneous coronary angioplasty - Acute and short term results
por: Rupesh Santosh Agrawal, et al.
Publicado: (2021)

Stroke of antiplatelet and anticoagulant therapy in patients with coronary artery disease: a meta-analysis of randomized controlled trials
por: Qiao Yu Shao, et al.
Publicado: (2021)

Uso de terapia antiagregante dual luego de angioplastía coronaria. Duración, frecuencia de sangramientos y validación de scores de riesgo de hemorragia en una cohorte chilena
por: Martínez,Gonzalo, et al.
Publicado: (2017)

Race and Drug Toxicity: A Study of Three Cardiovascular Drugs with Strong Pharmacogenetic Recommendations
por: Travis J. O’Brien, et al.
Publicado: (2021)

“TAP” technique on bifurcation lesion of Y graft in a patient with NSTEMI complicated with cardiogenic shock
por: Čanković Milenko, et al.
Publicado: (2021)

Anti-Platelet Fraction Isolated from Galega Officinalis
por: Atanasov A.
Publicado: (2016)

Efficacy and safety of ticagrelor versus clopidogrel in patients with non-ST-elevation myocardial infarction in Taiwan
por: Chih-Kuo Lee, et al.
Publicado: (2021)

Quality of life in patients with stable coronary artery disease submitted to percutaneous, surgical, and medical therapies: a cohort study
por: Lucas Molinari Veloso da Silveira, et al.
Publicado: (2021)

NORMAL CORONARY ANGIOGRAMS IN PATIENTS OF SUSPECTED CORONARY ARTERY DISEASE: A SIX YEAR STUDY AT ARMY CARDIAC CENTRE LAHORE
por: Ahmad Usman, et al.
Publicado: (2021)

One-year clinical outcomes in patients with very small coronary artery disease treated with drug-eluting stents: An observational study in the Indian population
por: Suhas P. Hardas, et al.
Publicado: (2021)